Boston

Cambridge flood
Business

Hurricanes, droughts, and wildfires: How biopharma is girding for climate change

By Kate Sheridan

Something ventured illo
Biotech

Something Ventured: Finch Therapeutics and three other startups got venture funding a year ago. Did it help them do what they said it would?

By Kate Sheridan

David A. Sinclair
Biotech

Longevity scientists launch academy to raise profile of life-extending research

By Robert Weisman — Boston Globe

Millipore CEO Udit Batra
Biotech

MilliporeSigma CEO Udit Batra on gene editing, business in China, and the company’s funky logo

By Kate Sheridan

Joel S. Marcus
Business

Real estate tycoon’s investment trust sues his son — and he responds in kind

By Jonathan Saltzman — Boston Globe

Jennifer Doudna
Biotech

University of California to be granted long-sought CRISPR patent, possibly reviving dispute with the Broad Institute

By Sharon Begley

Alexandria Ocasio-Cortez
Biotech

A tweet from Alexandria Ocasio-Cortez prompts a deeper debate over how drugs are made

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

A self-righting capsule
In the Lab

Scientists take a page from tortoises to design a new type of drug delivery

By Megan Thielking

Sarepta - hearing
Biotech

Solid Biosciences to soldier on as initial muscular dystrophy gene therapy results disappoint

By Matthew Herper

IV hand black background
Biotech

With new data, a biotech tries to relieve doubts about the durability of its gene therapy for Fabry disease

By Adam Feuerstein

Alexa in the hospitala
Health

New voices at patients’ bedsides: Amazon, Google, Microsoft, and Apple

By Casey Ross

Pharmalot
Pharmalot

Novartis and Vertex battle the Netherlands government over pricing

By Ed Silverman

Panning for gold
In the Lab

For CRISPR enzymes, the gold rush is on

By Sharon Begley

Josh Hillman
Health

‘We’re still waiting’: As cystic fibrosis drugs deliver new hope, not everyone is being swept up by scientific progress

By Andrew Joseph

Dana Farber Cancer Institute.
In the Lab

Dana-Farber heads to court to add researcher on immunotherapy patents

By Elizabeth Cooney

Vertex
Pharmalot

U.K. lawmaker challenges the government to issue a compulsory license for Vertex drug

By Ed Silverman

Purdue Pharma courthouse protest
Health

Massachusetts releases its full lawsuit against Purdue, the maker of OxyContin

By Andrew Joseph

Jack Stoddard
Business

No products yet, but ambitious Atul Gawande health venture to begin ‘deploying tests’ this year

By Kate Sheridan

Mitt Romney walks in Congress
Politics

Romney to drug industry CEOs: ‘Change is coming’

By Nicholas Florko

Dr. Atul Gawande
Business

In a heated court hearing, Atul Gawande’s new company and Optum fight to keep their own secrets

By Kate Sheridan and Casey Ross

Mitt Romney
Exclusive

Romney to speak before closed-door meeting of drug industry CEOs

By Nicholas Florko

Biotech

Roche’s Alzheimer’s failure increases tension for Biogen

By Matthew Herper

Marylou Sudders
Pharmalot

Here’s how Massachusetts officials hope to lower their Medicaid drug spending

By Ed Silverman

Millions of dollars
Biotech

Lyndra Therapeutics raises $55 million from Gilead and Gates

By Kate Sheridan

Pharma Court Protest - Boston
Health

Judge orders full release of redacted lawsuit against Purdue Pharma, maker of OxyContin

By Andrew Joseph

Alexion Pharmaceuticals Inc
Biotech

Alexion’s newly approved rare-disease drug notches another clinical trial win

By Adam Feuerstein

Using VR to see cancer
Play
Health

Watch: He wanted to see his cancer from the inside. With virtual reality, he can

By Dominic Smith

Optum
Business

Trade secrets case involving Atul Gawande’s company raises a key question: Who counts as a threat?

By Casey Ross and Kate Sheridan

Exclusive

In a sign of its concerns about Atul Gawande’s new venture, Optum sues over trade secrets

By Kate Sheridan and Casey Ross

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy